Healio Rheumatology Current Issue
The following articles appeared in the print edition of Healio Rheumatology.
Table of Contents
- Fewer Steroids, Longer Remission: Staying Ahead of Vasculitis
-
- Five Top Janus Kinase Inhibitor Articles
- Biologic Therapies for Inflammatory Bowel Disease Maria Laura Annunziata, MD, PhD; David T. Rubin, MD
- CHMP Issues Positive Opinion for Amgens Adalimumab Biosimilar
- CHMP Issues Positive Opinion for Xeljanz
- European Commission Approves Baricitinib for Rheumatoid Arthritis
- FDA Approves Siliq for Treating Psoriasis
- Health Canada Approves Kevzara for Rheumatoid Arthritis
- Humira Biosimilar Accepted for EMA, FDA Review
-
- Advances in Vasculitis: Notes From the Field Leonard H. Calabrese, DO
- CreakyJoints Publishes First Patient-Centered RA Guidelines
- Etanercept/MTX were Best of Three Treatments in Juvenile Idiopathic Arthritis
- Higher Bone Mineral Density Associated With Reduced Risk for Hip Osteoarthritis
- Infliximab Given Within 4 Weeks Prior to Arthroplasty Showed No Increased Infection Rate
- Lifetime Risk of Total Hip Replacement Likely to Increase for Patients With OA
- Patients With Lupus Showed Three-Fold Increased Risk for Heart Attack
- Researchers Develop Metric to Measure B Cells That Drive Rheumatoid Arthritis
-
- Sirukumab Effective for Anti-TNF Intolerant RA
- Study Finds KOOS Scales Valid, Responsive for TKR Patients
- Tofacitinib Seen as Safe, Effective in Patients With Ankylosing Spondylitis
- Biologic Discontinuation Rates Increased During the Past Decade
- Light Physical Activity Reduced Risk of Limitation from Osteoarthritis
- Long-Term Extension Studies on Tofacitinib: Discontinuation Most Commonly Associated With Adverse Events
- Secukinumab Seen as Effective, Cost-Efficient Treatment for Psoriatic Arthritis